Lawsuits surrounding Merck's HPV vaccine Gardasil have been piling up for years now, but they've garnered increased public ...

A lawsuit involving Merck's Gardasil in Los Angeles has been adjourned and will reconvene with a new jury. Read more here.

Merck & Co.’s first trial over the safety of its blockbuster Gardasil cancer vaccine was cut short and rescheduled amid ...

Merck and a plaintiff have paused a trial over alleged injuries from the HPV vaccine Gardasil, with ties to HHS Secretary ...

Merck and a plaintiff have paused a trial over potential Gardasil injuries, with ties to Health Secretary Robert F. Kennedy Jr. The trial resumes in September. Kennedy, involved in mass litigation ...

Merck posted Q4 sales of $15.62 billion, driven by Keytruda's 19% growth. FY25 guidance lags estimates, citing Gardasil shipment pause in China and forex impact.

Shares of Merck are sliding in early trading after the drugmaker surprised Wall Street with a lower-than-expected 2025 sales ...

They're all talking about HPV, or human papillomavirus. It's the most common sexually transmitted infection, but it's also ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Pause on Gardasil China sales from Feb to at least mid-2025 Keytruda beats, Gardasil misses Q4 sales estimates Merck pulls Gardasil's long-term sales target Shares tumble 11% in early trading Feb ...

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US ...

Executives pulled back on a 2030 sales target of $11 billion as demand for the HPV shot shrinks amid China market turmoil.